Axa
ENTA icon

Axa’s Enanta Pharmaceuticals ENTA Stock Holding History

Axa’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-31,300
Closed -$670K – 1091
2023
Q2 		$670K Buy
+31,300
New +$923K ﹤0.01% 908
2023
Q1 		– Sell
-6,200
Closed -$288K – 1127
2022
Q4 		$288K Hold
6,200
– – ﹤0.01% 1055
2022
Q3 		$322K Buy
+6,200
New +$362K ﹤0.01% 1026
2021
Q3 		– Sell
-62,400
Closed -$2.75M – 1251
2021
Q2 		$2.75M Buy
62,400
+23,253
+59% +$1.14M 0.01% 828
2021
Q1 		$1.93M Buy
39,147
+31,047
+383% +$1.55M 0.01% 855
2020
Q4 		$341K Buy
8,100
+300
+4% +$13.2K ﹤0.01% 1123
2020
Q3 		$357K Hold
7,800
– – ﹤0.01% 1093
2020
Q2 		$392K Buy
+7,800
New +$404K ﹤0.01% 1095
2019
Q1 		– Sell
-3,300
Closed -$234K – 1331
2018
Q4 		$234K Sell
3,300
-12,000
-78% -$920K ﹤0.01% 1208
2018
Q3 		$1.31M Sell
15,300
-2,100
-12% -$210K ﹤0.01% 976
2018
Q2 		$2.02M Buy
+17,400
New +$1.74M 0.01% 850
2015
Q4 		– Sell
-36,590
Closed -$1.32M – 1421
2015
Q3 		$1.32M Buy
+36,590
New +$1.57M 0.01% 859
2015
Q2 		– Sell
-30,350
Closed -$929K – 1421
2015
Q1 		$929K Buy
30,350
+550
+2% +$21.4K ﹤0.01% 969
2014
Q4 		$1.51M Buy
29,800
+17,500
+142% +$783K 0.01% 864
2014
Q3 		$487K Buy
+12,300
New +$490K ﹤0.01% 1074

Other funds holding ENTA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Axa's ENTA Position: Q3 2023 in Review

Axa sold out of Enanta Pharmaceuticals (ENTA) in Q3 2023, closing a stake of 31,300 shares — an estimated $670K sold.

Axa first reported a position in ENTA in Q3 2014 and held it in 15 quarters. The position peaked at $2.75M in Q2 2021. 132 funds tracked by Wall St. Rank hold ENTA as of Q3 2023.

  • Axa reported no remaining Enanta Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Axa sold 31,300 Enanta Pharmaceuticals shares in Q3 2023, an estimated $670K.
  • Axa first reported a position in Enanta Pharmaceuticals in Q3 2014 and held it in 15 quarters.
  • Axa's Enanta Pharmaceuticals position peaked at $2.75M in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2023.

Based on Axa's 13F filing for Q3 2023, filed 14 Nov 2023.